Press Release

Date: 24th July 2026 The Manager Listing Compliance Department National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051, India Symbol: SAKAR Sub: Press Release - Consolidated and Standalone Un-audited Financial Results for the quarter ended June 30, 2026. In continuation of outcome of Board meeting held on Friday, 24th July 2026 on the Consolidated and Standalone Un-audited Financial Results for the quarter ended June 30, 2026 we attach a copy of Press Release being issued by the Company. This is for information and records. Thanking You, Yours faithfully, FOR, SAKAR HEALTHCARE LIMITED BHARAT SONI COMPANY SECRETARY AND COMPLIANCE OFFICER Encl: As above Q1FY27 – Sakar Healthcare Records 38% YoY Revenue Growth PAT Rises 120% Ahmedabad, 24th July 2026 : Sakar Healthcare Ltd |NSE: SAKAR, with a research-driven API- integrated EU GMP approved oncology orals and injection manufacturing unit, has announced its unaudited financial results for the financial year ended 30th Jun 2026. Q1FY27 Consolidated Financial Performance Particulars (INR Lakhs) Q1FY27 Q1FY26 Y-o-Y FY26 Revenue from Operations 7,297.25 5,273.62 38% 25,173.60 Gross Profit 3,839.03 2,378.38 61% 12,845.93 Gross Profit Margin (%) 53% 45% 51% EBITDA 2,124.89 1,270.58 67% 6,888.82 EBITDA Margin (%) 29% 24% 27% Profit After Tax 1,028.49 467.13 120% 3,048.46 PAT Margin 14% 9% 12% Business Highlights for Q1FY27 • Executed more than 65 oncology product contracts, with over 50 commercial discussions currently underway. • Shared 261 dossiers globally, of which 178 have been submitted and 16 have received Marketing Authorisations. • Shared dossiers for 21 of the 32 developed oncology products, securing 16 dossier approvals. • Completed 26 EU Marketing Authorisation filings, including 15 owned filings. Further 6 MAs procured through partners in Bulgaria and Bosnia, rest has been filed that includes Czech Republic, Croatia and Portugal. • Sakar Healthcare continues to strengthen its foundation for long-term value creation, backed by robust growth, expanding oncology capabilities, and a growing global footprint. • Submitted 33 site variations covering 18 cytotoxic molecules across the EU and the UK, of which seven have been approved. • Developed 21 APIs in-house, including, 16 APIs with Written Confirmation, 8 Commercialised products, 2 API’s with CEP approval, 5 CEP applications currently in process. • 33 Technology transfer projects for oncology products are underway with Accord-Intas, Torrent in the UK and Germany, Emcure, Glenmark, and Zydus. Of these projects, 7 have received site variation approvals—two in the UK and five in the EU. Financial Highlights for Q1 & FY27 • Revenue from operations for Q1FY27 stood at ₹ 7,297 lakhs, reflecting 38% YoY growth. Performance was supported by new market authorizations with oncology products and strong demand across countries, alongside continued execution across key initiatives • EBITDA increased to ₹ 2,125 lakhs, up 67% YoY; EBITDA margins stood at 29% • Company delivered a strong improvement in profitability, with PAT margin at 14% expanding sharply YoY, reflecting operating leverage, improved efficiencies, and disciplined cost management Commenting on the Results, Mr. Sanjay Shah, Managing Director said, Q1FY27 marks another period of steady progress, supported by healthy year-on-year growth. The company remains on a strong growth trajectory in terms of both revenue and profitability, reinforcing the promising outlook for the business over the longer term. Our Oncology business remains a key pillar of our strategy. During the quarter, we expanded commercial engagements, strengthened export momentum, and advanced dossier submissions, Marketing Authorizations, site variation approvals, and technology transfer projects with leading global pharmaceutical partners. We also enhanced our integrated oncology platform by expanding our portfolio of in- house APIs supported by key regulatory certifications, reinforcing our capabilities and long-term competitive position. Looking ahead, we remain confident that converting regulatory approvals into commercial launches and supplies, alongside growing export opportunities and the gradual ramp-up of oncology volumes, will improve capacity utilisation and operating leverage. Backed by a robust product pipeline, regulatory progress, and an expanding international presence, we are well positioned to deliver sustainable and profitable growth. Our long-term outlook remains promising, underpinned by the scalability of our oncology platform and the progressive commercialization of our product portfolio About Sakar HealthCare Limited: Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high- potent oncology products. Sakar’s oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs, underscoring its commitment to innovation and quality. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations. Driven by its vision to deliver world-class healthcare solutions that make lives healthier and more meaningful, Sakar continues to expand its presence across regulated markets through strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles. Contact Details Sakar HealthCare Limited Investor Relations: MUFG Intime India Private Limited CIN - L24231GJ2004PLC043861 Mr. Nikunj Seth | Ms. Sejal Bhattar Mr. Dharmesh Thaker nikunj.seth@in.mpms.mufg.com sejal.bhattar@in.mpms.mufg.com Sianffeo@ Hsaarkbaorhr eSatlathtceamree.cnotm Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections,interest, and other costs.The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.